NASDAQ:RNA - Prosensa Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$18.65
Today's RangeN/A
52-Week Range$4.12 - $22.80
VolumeN/A
Average Volume157,108 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. The Company's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company's platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

Receive RNA News and Ratings via Email

Sign-up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:RNA
CUSIPN/A
Phone+31-71-3322100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Prosensa (NASDAQ:RNA) Frequently Asked Questions

What is Prosensa's stock symbol?

Prosensa trades on the NASDAQ under the ticker symbol "RNA."

Has Prosensa been receiving favorable news coverage?

News coverage about RNA stock has trended somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Prosensa earned a news impact score of 0.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near future.

What other stocks do shareholders of Prosensa own?

How do I buy shares of Prosensa?

Shares of RNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prosensa's official website?

The official website for Prosensa is http://www.prosensa.eu.

How can I contact Prosensa?

Prosensa's mailing address is J.H. Oortweg 21, LEIDEN, 2333 CH, Netherlands. The biotechnology company can be reached via phone at +31-71-3322100.


MarketBeat Community Rating for Prosensa (NASDAQ RNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Prosensa and other stocks. Vote "Outperform" if you believe RNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel